Bicara Therapeutics director files initial ownership

Bicara Therapeutics Inc. submitted an initial beneficial ownership report for director Christy J. Oliger.

Accepted by SEC EDGAR 07/29/2026 - 04:17 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Bicara Therapeutics Inc. submitted an initial beneficial ownership report for director Christy J. Oliger. The report lists no equity or derivative security transactions and does not list any current holdings or derivative positions. A remark references Exhibit 24, identified as a Power of Attorney.

Key Figures

Reported purchase transactions: 0 Reported sale transactions: 0 Reported derivative transactions: 0

3 metrics

Reported purchase transactions 0 BuyCount in the transaction summary

Reported sale transactions 0 SellCount in the transaction summary

Reported derivative transactions 0 DerivativeTransactionCount in the transaction summary

Key Terms

Power of Attorney, reporting person

2 terms

Power of Attorney regulatory

"Remarks note: "Exhibit 24 - Power of Attorney""

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

reporting person regulatory

"The JSON identifies "reportingPersons" with role details"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Bicara Therapeutics (BCAX) report in this Form 3 for Christy J. Oliger?

The Form 3 reports Christy J. Oliger as a director of Bicara Therapeutics Inc.. It shows no listed equity or derivative holdings and no insider transactions at the time of this initial beneficial ownership statement.

Are any insider stock purchases or sales reported for BCAX in this Form 3?

No insider stock purchases or sales are reported. The transaction summary shows 0 buy and 0 sell entries, indicating no equity transactions are listed in this initial ownership report.

Does the Bicara Therapeutics (BCAX) Form 3 list any derivative securities?

No derivative securities are listed. The filing’s derivative transaction count is 0, and the derivative positions section is empty, so no options or other derivative positions are reported in this statement.

What role does Christy J. Oliger have at Bicara Therapeutics (BCAX)?

Christy J. Oliger is identified as a director of Bicara Therapeutics Inc. The Form 3 indicates director status and provides an initial disclosure of beneficial ownership, without listing any current securities positions.

What is the significance of Exhibit 24 in this BCAX Form 3?

The remarks section references Exhibit 24 - Power of Attorney. This indicates a Power of Attorney document is attached as an exhibit, typically authorizing designated individuals to execute and submit SEC-related documents on the reporting person’s behalf.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Oliger Christy J.

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/28/2026

3. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Ryan Cohlhepp, Attorney-in-Fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)